| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | NaN | 69,802 | NaN | NaN |
| Employee related expenses | NaN | 18,648 | NaN | NaN |
| Commercial related expenses | NaN | 6,983 | NaN | NaN |
| Cost of product sales | NaN | 5,955 | NaN | NaN |
| Consultants and third-party services | NaN | 4,395 | NaN | NaN |
| Outside clinical trial related expenses | NaN | 6,945 | NaN | NaN |
| Other segment items | NaN | 3,706 | NaN | NaN |
| Total revenues | 58,818 | NaN | NaN | NaN |
| Interest expense, net | NaN | -6,822 | NaN | NaN |
| Employee related expenses | 21,002 | NaN | NaN | NaN |
| Commercial related expenses | 7,040 | NaN | NaN | NaN |
| Outside clinical trial related expenses | 6,927 | NaN | NaN | NaN |
| Cost of product sales | 4,606 | NaN | NaN | NaN |
| Consultants and third-party services | 4,006 | NaN | NaN | NaN |
| Other segment items | 3,352 | NaN | NaN | NaN |
| Interest expense, net | -228 | NaN | NaN | NaN |
| (benefit from) provision for income taxes | NaN | -245,351 | NaN | NaN |
| Provision for income taxes | 3,003 | NaN | NaN | NaN |
| Net income | 8,654 | 268,065 | 27,900 | 71,059 |
| Stock-based compensation expense | 3,456 | 2,748 | 3,363 | 6,600 |
| (gain) loss on sale and disposal of fixed assets | NaN | 0 | NaN | NaN |
| Depreciation and amortization | 597 | 601 | 603 | 1,211 |
| Deferred income tax | 2,573 | -245,852 | NaN | NaN |
| Release of cost share liability | NaN | 0 | 0 | 39,981 |
| Net amortization of discount on short-term investments and term loans | 170 | 243 | 467 | 440 |
| Accounts receivable, net | -1,818 | 5,838 | 6,018 | -1,708 |
| Inventories | 581 | -1,131 | -188 | 6,954 |
| Prepaid and other current and non-current assets | 3,792 | 3,387 | 1,872 | 6,589 |
| Right-of-use assets | 135 | 130 | 128 | -932 |
| Accounts payable | -2,705 | 3,345 | -3,444 | 3,951 |
| Accrued compensation | -5,905 | 1,849 | 2,168 | -2,242 |
| Accrued research and development | 218 | 708 | 695 | 48 |
| Revenue reserves and refund liability | 364 | -2,304 | 518 | 3,062 |
| Other current and long-term liabilities | NaN | -285 | NaN | NaN |
| Other accrued liabilities | -339 | NaN | 350 | -1,803 |
| Lease liabilities | -145 | -141 | -81 | 946 |
| Net cash provided by (used in) operating activities | 2,725 | 21,980 | 24,031 | 29,644 |
| Maturities of short-term investments | 15,945 | 13,549 | 20,730 | 26,850 |
| Purchases of short-term investments | 23,920 | 38,923 | 53,893 | 60,678 |
| Capital expenditures | NaN | -12 | 12 | NaN |
| Payments for acquisition of intangible assets | NaN | 0 | NaN | NaN |
| Proceeds from sale of property and equipment | NaN | 0 | NaN | NaN |
| Net cash used in investing activities | -7,975 | -25,362 | -33,175 | -33,828 |
| Net proceeds from term loan financing | NaN | 0 | NaN | NaN |
| Principal payments of term loans | 7,500 | 7,500 | NaN | NaN |
| Net proceeds from issuance of common stock under equity plans | 321 | 2,928 | 4,271 | 902 |
| Closing purchase price payment related to asset acquisition | NaN | 0 | NaN | NaN |
| Cost share payments to a collaboration partner | NaN | 0 | NaN | NaN |
| Repurchases of common stock in connection with employee tax withholding on rsu vesting | 3,740 | NaN | NaN | NaN |
| Net cash (used in) provided by financing activities | -10,919 | -4,572 | 4,271 | 902 |
| Net decrease in cash, cash equivalents and restricted cash | -16,169 | -7,954 | -4,873 | -3,282 |
| Cash, cash equivalents, and restricted cash at beginning of period | 40,637 | 48,591 | 56,746 | NaN |
| Cash, cash equivalents, and restricted cash at end of period | 24,468 | 40,637 | 48,591 | NaN |
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)